{"pmid":32384183,"title":"In-hospital management of persons with haemophilia and COVID-19: practical guidance.","text":["In-hospital management of persons with haemophilia and COVID-19: practical guidance.","A new disease (COVID-19) caused by a coronavirus (SARS-CoV-2) that appeared in China at the end of 2019 is currently spreading globally. This emerging virus is mainly responsible for respiratory tract infections and potentially fatal pneumonia, mainly in more frail patients. Persons with haemophilia of variable severity and from all parts of the world will likely be infected and develop COVID-19. We here propose practical guidance for the in-hospital specific management of haemophilia persons with COVID-19 including their possible transfer to intensive care unit. Rapid identification of the haemophilia status, undelayed and regular liaison with the haemophilia team, proper therapy with factor concentrates or alternative treatments appear instrumental to prevent haemophilia-related complications in this setting. Information of patients and their families about COVID-19, psychological support and good appreciation of the impact of haemophilia on therapeutic decisions including end of life directives are also addressed.","Haemophilia","Hermans, Cedric","Lambert, Catherine","Sogorb, Amaury","Wittebole, Xavier","Belkhir, Leila","Yombi, Jean Cyr","32384183"],"abstract":["A new disease (COVID-19) caused by a coronavirus (SARS-CoV-2) that appeared in China at the end of 2019 is currently spreading globally. This emerging virus is mainly responsible for respiratory tract infections and potentially fatal pneumonia, mainly in more frail patients. Persons with haemophilia of variable severity and from all parts of the world will likely be infected and develop COVID-19. We here propose practical guidance for the in-hospital specific management of haemophilia persons with COVID-19 including their possible transfer to intensive care unit. Rapid identification of the haemophilia status, undelayed and regular liaison with the haemophilia team, proper therapy with factor concentrates or alternative treatments appear instrumental to prevent haemophilia-related complications in this setting. Information of patients and their families about COVID-19, psychological support and good appreciation of the impact of haemophilia on therapeutic decisions including end of life directives are also addressed."],"journal":"Haemophilia","authors":["Hermans, Cedric","Lambert, Catherine","Sogorb, Amaury","Wittebole, Xavier","Belkhir, Leila","Yombi, Jean Cyr"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32384183","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/hae.14045","keywords":["covid-19","guidance","sars-cov2","haemophilia"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1666267276718899202,"score":9.490897,"similar":[{"pmid":32426896,"title":"Intra-articular injections in people with haemophilia in the COVID-19 era.","text":["Intra-articular injections in people with haemophilia in the COVID-19 era.","Given the current SARS-CoV-2 pandemic, many patients with haemophilia will have close contact with a confirmed case or suffer from coronavirus 2019 respiratory disease (COVID-19) and will need medical attention. Considering that this situation is exceptional, it is necessary to carry out integrated assistance for patients with haemophilia patients and their relatives, focusing such assistance on all the dimensions of life. In this regard, the WFH's recommendations to optimise haematological prophylaxis and its adherence should be emphasised to minimise the risk of bleeding and thus reduce the need to visit health care facilities [1].","Haemophilia","De la Corte-Rodriguez, Hortensia","Rodriguez-Merchan, E Carlos","Alvarez-Roman, M Teresa","Jimenez-Yuste, Victor","32426896"],"abstract":["Given the current SARS-CoV-2 pandemic, many patients with haemophilia will have close contact with a confirmed case or suffer from coronavirus 2019 respiratory disease (COVID-19) and will need medical attention. Considering that this situation is exceptional, it is necessary to carry out integrated assistance for patients with haemophilia patients and their relatives, focusing such assistance on all the dimensions of life. In this regard, the WFH's recommendations to optimise haematological prophylaxis and its adherence should be emphasised to minimise the risk of bleeding and thus reduce the need to visit health care facilities [1]."],"journal":"Haemophilia","authors":["De la Corte-Rodriguez, Hortensia","Rodriguez-Merchan, E Carlos","Alvarez-Roman, M Teresa","Jimenez-Yuste, Victor"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426896","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/hae.14070","locations":["Intra"],"topics":["Prevention"],"weight":1,"_version_":1667352728826806272,"score":424.39618},{"pmid":32397000,"title":"The role of telemedicine in the delivery of healthcare in the COVID-19 Pandemic.","text":["The role of telemedicine in the delivery of healthcare in the COVID-19 Pandemic.","On 11 March 2020, the World Health Organization declared the coronavirus disease 2019 (COVID-19) a pandemic. Recently, Hermans, et.al., outlined the challenges the COVID-19 pandemic pose for the bleeding disorders community (1) . The general response to the pandemic has included increased measures focused on personal hygiene, social distancing, symptom monitoring, early diagnosis, patient isolation, shelter in place, and public health quarantine. Accordingly, such measures have led to concerns over how to maintain access to haemophilia treatment products and to the specialized integrated care medical follow up within the haemophilia treatment centers (HTCs). As part of the medical response to disasters such as a world-wide pandemic, telemedicine has emerged as one proposed solution to address this type of global challenge (2) .","Haemophilia","Valentino, Leonard A","Skinner, Mark W","Pipe, Steven","32397000"],"abstract":["On 11 March 2020, the World Health Organization declared the coronavirus disease 2019 (COVID-19) a pandemic. Recently, Hermans, et.al., outlined the challenges the COVID-19 pandemic pose for the bleeding disorders community (1) . The general response to the pandemic has included increased measures focused on personal hygiene, social distancing, symptom monitoring, early diagnosis, patient isolation, shelter in place, and public health quarantine. Accordingly, such measures have led to concerns over how to maintain access to haemophilia treatment products and to the specialized integrated care medical follow up within the haemophilia treatment centers (HTCs). As part of the medical response to disasters such as a world-wide pandemic, telemedicine has emerged as one proposed solution to address this type of global challenge (2) ."],"journal":"Haemophilia","authors":["Valentino, Leonard A","Skinner, Mark W","Pipe, Steven"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32397000","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/hae.14044","locations":["Hermans","et.al."],"topics":["Prevention"],"weight":1,"_version_":1666627827879903233,"score":390.66473},{"pmid":32282993,"title":"DOACs and 'newer' haemophilia therapies in COVID-19.","text":["DOACs and 'newer' haemophilia therapies in COVID-19.","We would like to thank the authors for their insightful thoughts on the consideration of anticoagulants and treatment for haemophilia A and B during the COVID-19 pandemic. They highlight some important practical points which certainly should be adopted by the thrombosis and haemostasis community in the current situation of restricted mobility, which reduces the possibility for patients to access general practitioners and hospitals.","J Thromb Haemost","Thachil, Jecko","Tang, Ning","Gando, Satoshi","Falanga, Anna","Cattaneo, Marco","Levi, Marcel","Clark, Cary","Iba, Toshiaki","32282993"],"abstract":["We would like to thank the authors for their insightful thoughts on the consideration of anticoagulants and treatment for haemophilia A and B during the COVID-19 pandemic. They highlight some important practical points which certainly should be adopted by the thrombosis and haemostasis community in the current situation of restricted mobility, which reduces the possibility for patients to access general practitioners and hospitals."],"journal":"J Thromb Haemost","authors":["Thachil, Jecko","Tang, Ning","Gando, Satoshi","Falanga, Anna","Cattaneo, Marco","Levi, Marcel","Clark, Cary","Iba, Toshiaki"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282993","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14841","topics":["Treatment"],"weight":1,"_version_":1666138491475460096,"score":378.1889},{"pmid":32294321,"title":"Impact of the COVID-19 pandemic on therapeutic choices in Thrombosis-Hemostasis.","text":["Impact of the COVID-19 pandemic on therapeutic choices in Thrombosis-Hemostasis.","Major therapeutic developments have been achieved in the field of thrombotic and hemorrhagic diseases over the last decade. These include the development and validation of four direct oral anticoagulants (DOACs) indicated for numerous thrombotic disorders, both arterial and venous [1]. It also involves new haemostatic agents for hemophilia patients, in particular Factor VIII (FVIII) and Factor IX (FIX) concentrates with extended half-life (EHL) [2;3] and a bispecific antibody mimicking the action of FVIII (Emicizumab) [4;5].","J Thromb Haemost","Hermans, C","Lambert, C","32294321"],"abstract":["Major therapeutic developments have been achieved in the field of thrombotic and hemorrhagic diseases over the last decade. These include the development and validation of four direct oral anticoagulants (DOACs) indicated for numerous thrombotic disorders, both arterial and venous [1]. It also involves new haemostatic agents for hemophilia patients, in particular Factor VIII (FVIII) and Factor IX (FIX) concentrates with extended half-life (EHL) [2;3] and a bispecific antibody mimicking the action of FVIII (Emicizumab) [4;5]."],"journal":"J Thromb Haemost","authors":["Hermans, C","Lambert, C"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294321","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14845","keywords":["covid-19","emicizumab","pandemic","clotting factor concentrates","direct oral anticoagulants","hemophilia"],"topics":["Treatment"],"weight":1,"_version_":1666138494521573376,"score":337.9815},{"pmid":32492753,"title":"Recovery from COVID-19 following Hepatitis C, Human Immunodeficiency Virus Infection and Liver Transplantation.","text":["Recovery from COVID-19 following Hepatitis C, Human Immunodeficiency Virus Infection and Liver Transplantation.","Immunosuppression and frequent comorbidities in transplant recipients potentially increase the risk of fatal outcomes of pandemic coronavirus disease 2019 (COVID-19) [1]. A 1965 born male had suffered from haemophilia A. In the nineteen-seventies, he acquired hepatitis C virus (HCV) infection, probably via factor VIII supplementation, and in 1985 human immunodeficiency virus (HIV) infection. Interferon-based HCV therapy resulted in a sustained virological response. Antiviral treatment with emtricitabine/tenofovir alafenamide/rilpivirin for HIV is ongoing since 2016. HIV suppression with repeatedly negative PCR results has been achieved.","Am J Transplant","Muller, Helmut","Kniepeiss, Daniela","Stauber, Rudolf","Schrem, Harald","Rauter, Markus","Krause, Robert","Schemmer, Peter","32492753"],"abstract":["Immunosuppression and frequent comorbidities in transplant recipients potentially increase the risk of fatal outcomes of pandemic coronavirus disease 2019 (COVID-19) [1]. A 1965 born male had suffered from haemophilia A. In the nineteen-seventies, he acquired hepatitis C virus (HCV) infection, probably via factor VIII supplementation, and in 1985 human immunodeficiency virus (HIV) infection. Interferon-based HCV therapy resulted in a sustained virological response. Antiviral treatment with emtricitabine/tenofovir alafenamide/rilpivirin for HIV is ongoing since 2016. HIV suppression with repeatedly negative PCR results has been achieved."],"journal":"Am J Transplant","authors":["Muller, Helmut","Kniepeiss, Daniela","Stauber, Rudolf","Schrem, Harald","Rauter, Markus","Krause, Robert","Schemmer, Peter"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32492753","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/ajt.16107","locations":["VIII"],"topics":["Case Report"],"weight":1,"_version_":1668623433700737025,"score":298.35126}]}